Working closely with the forensic community, Verogen places exceptional value on flexible, scalable solutions that deliver reliable results. Verogen’s sequencing and analysis solutions are designed for use on the MiSeq FGx® Sequencing System from Illumina, Inc. With this acquisition, QIAGEN gains exclusive distribution rights for this version of the MiSeq sequencer designed specifically for forensics applications. More than 300 MiSeq FGx Sequencing Systems have been placed to date, marking a strong entry into this market segment.
- We’d like to share more about how we work and what drives our day-to-day business.
- We identify bottlenecks, solve problems and exceed expectations.
- GEDmatch allows users to upload genetic profiles created by other genealogy sites in order to expand the search for familial links; it currently contains more than 1.8 million genealogical profiles and continues to grow.
- Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice.
- After adjusting our near-term assumptions a bit, we do not anticipate changing our fair value estimate for Qiagen at first glance.
Analytical instruments company Thermo Fisher Scientific Inc. reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life scienc… Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases. QIAGEN and Verogen have been commercialization partners since announcing a distribution agreement in June 2021.
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. Qiagen NV (Qiagen) is a provider of molecular testing solutions.
Products and Services
QIAGEN recently completed the full acquisition of Verogen for $150 million in cash paid from existing reserves. QIAGEN currently expects about $20 million of sales from the Verogen portfolio in 2023, building on about $5 million of sales for QIAGEN in 2022 from the distribution agreement. Due to planned investments for commercialization and portfolio development, the transaction is expected to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and neutral to adjusted EPS in 2024. QIAGEN also gains full access to Verogen’s pioneering GEDmatch database and GEDmatch PRO™ portal. GEDmatch allows users to upload genetic profiles created by other genealogy sites in order to expand the search for familial links; it currently contains more than 1.8 million genealogical profiles and continues to grow. GEDmatch PRO™ is designed to support police and forensic teams with investigative comparisons to data uploaded by consenting GEDmatch users.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Qiagen’s second-quarter results mildly exceeded expectations, even when considering the significant COVID-19-related declines versus a tough comparable period in 2022. However, management trimmed its 2023 guidance due to more severe retrenching activities at some customers, similar to recent trends we have seen at other life science toolmakers. After adjusting our near-term assumptions a bit, we do not anticipate changing our fair value estimate for Qiagen at first glance.
In 2022, Qiagen’s revenue was $2.14 billion, a decrease of -4.89% compared to the previous year’s $2.25 billion. Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of QGEN’s
Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable res… New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysa… Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Qiagen shares surged 19% to 37.84 euros after Thermo Fisher Scientific said it would buy the diagnostics firm for 39 euros per share in cash, which is a 23% premium to Monday’s close. Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people…
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations.
Our desire to innovate is driven by our customers passion in their fields. From doctors seeking solutions to diagnose and prevent disease, to researchers conquering new scientific frontiers and translating genomic insights into new medicines, we are inspired by their discoveries and breakthroughs. To opt-in for investor email alerts, https://bigbostrade.com/ please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. Transparent, evidence-based NGS interpretation and reporting.
It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Qiagen NV raised its outlook for 2020 and 2021 on Tuesday after increasing production amid the coronavirus pandemic. The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%… High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
How big is Qiagen NV?
QIAGEN – which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples – already has a leading position in the HID / forensics market. QIAGEN’s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories and criminal investigators. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. QIAGEN offers advanced molecular testing solutions that move customers through the whole process – faster, better and more efficiently.
We’d like to share more about how we work and what drives our day-to-day business. QGEN’s beta can be found in Trading Information at the commodity trading strategy top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Davidson Kempner was notable as having continued to reject the bid. Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses. Within a week of the collapse of the merger, QIAGEN’s stock rose over 10%. In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets. International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy …
- Qiagen NV raised its outlook for 2020 and 2021 on Tuesday after increasing production amid the coronavirus pandemic.
- Human identification DNA techniques have evolved greatly over the past few decades, helping to meet huge challenges like in the aftermaths of wars and natural disasters, as well as to support advances in criminal justice.
- Style is calculated by combining value and growth scores, which are first individually calculated.
- The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%…
- Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services.
Our product portfolio supports our customers across the continuum of molecular testing in molecular diagnostics and life sciences. Our automation systems bring together all of these steps in seamless end-to-end workflows. Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
The company’s sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm’s revenue (45% of 2021 sales), followed by EMEA (36%), and Asia-Pacific (19%). QIAGEN is targeting market segments with promising growth opportunities. At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process. Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples.
IT Client Prospector provides intelligence on Qiagen NV’s likely spend across technology areas enabling you to understand the digital strategy. A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world. A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included. Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances.
Our Outlook for Health-Care Stocks
In 2018, QIAGEN transferred its listing to New York Stock Exchange. In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform. Slumped 4.5% in morning trading Monday, reversing an earlier intraday gain of as much 1.7%, after the Netherlands-based biotechnology company provided an upbeat second-quarter revenue outlook, citing… Human identification DNA techniques have evolved greatly over the past few decades, helping to meet huge challenges like in the aftermaths of wars and natural disasters, as well as to support advances in criminal justice. As just one example, the International Commission on Missing Persons in the Netherlands to date has profiled more than 44,000 bone samples and made more than 18,000 identifications – all processed using QIAGEN chemistry and kits. Improve competitive bidding with insights into all publicly disclosed IT services contracts for Qiagen NV (including IT outsourcing, business process outsourcing, systems integration & consulting and more). Qiagen NV lost about one-fifth of its market value on Thursday after the Dutch biotechnology company said earlier this week that it would focus on its stand-alone business strategy, rejecting possible suitors.
It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Offers molecular diagnostics, applied testing, academic and pharmaceutical research. It also offers secondary sample technology consumable (kits and components for purification of nucleic acids, instruments for nucleic acid purification, and accessories). Qiagen N.V was founded in 1986 and is headquartered in Venlo, the Netherlands.
Since early 2020, QIAGEN worked closely with governments, public health authorities, and customers worldwide to ensure the availability of critical COVID-19 testing diagnostics, covering the needs of clinical and research customers. The tests and kits cover manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to detecting previous viral exposure. Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business.
However, the limitations of today’s broadly used workflows based on short-tandem-repeat (STR) analyses using capillary electrophoresis (CE) technology impede matches in an estimated 60-85% of traditional searches. This has resulted in a backlog of about 1 million unsolved cases in the U.S. alone. News, testing solutions and stories covering global efforts in the fight against COVID-19.